Spectral AI (Spectral AI) Interest Coverage : 0 (At Loss) (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Spectral AI Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Spectral AI's Operating Income for the three months ended in Mar. 2024 was $-2.14 Mil. Spectral AI's Interest Expense for the three months ended in Mar. 2024 was $-0.28 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Spectral AI's Interest Coverage or its related term are showing as below:

MDAI's Interest Coverage is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 17.5
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Spectral AI Interest Coverage Historical Data

The historical data trend for Spectral AI's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Spectral AI Interest Coverage Chart

Spectral AI Annual Data

Trend

Dec21

Dec22

Dec23

Interest Coverage

N/A

No Debt

Spectral AI Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Interest Coverage	Get a 7-Day Free Trial			N/A	N/A	N/A	No Debt	-

Competitive Comparison of Spectral AI's Interest Coverage

For the Medical Devices subindustry, Spectral AI's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spectral AI's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Spectral AI's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Spectral AI's Interest Coverage falls into.

Spectral AI Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Spectral AI's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Spectral AI's Interest Expense was $0.00 Mil. Its Operating Income was $-12.98 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Spectral AI had no debt ⁽¹⁾.

Spectral AI's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Spectral AI's Interest Expense was $-0.28 Mil. Its Operating Income was $-2.14 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Spectral AI did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Spectral AI (NAS:MDAI) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Spectral AI Interest Coverage Related Terms

Thank you for viewing the detailed overview of Spectral AI's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Spectral AI (Spectral AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Spectral AI Inc (NAS:MDAI) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

2515 McKinney Avenue, Suite 1000, Dallas, TX, USA, 75201

Website

https://www.spectralmd.com

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely and informed decision regarding the treatment of the patient's wound.

Executives

John Michael Dimaio	10 percent owner	6125 LUTHER LANE, DALLAS TX 75225
Michael Patrick Murphy	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Els 1960 Family, L.p.	10 percent owner	2323 VICTORY AVE., SUITE. 700, DALLAS TX 75219
Richard John Cotton	director	RUE DU VILLAGE 4, CHAMPERY V8 1874
Mellish Martin C.b.	director	13 BERRILL FARMS LN, HANOVER NH 03755
Jeffrey Edward Thatcher	officer: Chief Scientist	6659 ESCONDIDO ST, IRVING TX 75039
Nils Windler	officer: Chief Financial Officer	8602 NAPA LANDING, SAN ANTONIO TX 78015
Wensheng Fan	director, officer: CHIEF EXECUTIVE OFFICER	3320 SPRING MOUNTAIN DRIVE, PLANO TX 75025
Vincent S. Capone	officer: GENERAL COUNSEL	1620 GRASSHOPPER LANE, LOWER GWYNEDD PA 19002
Nikolaos Pagoulatos	officer: CHIEF OPERATING OFFICER	5122 IROQUOIS DR, FRISCO TX 75034
Xiaojia Cynthia Cai	director	10 CELESTIAL WAY, NEWARK DE 19711
Heather Bellini	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Edmonds Franklin S. Jr.	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Rosecliff Acquisition Sponsor I Llc	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Erich Spangenberg	10 percent owner	73 595 EL PASEO, SUITE 2204, PALM DESERT CA 92260